Healthcare / BiotechnologyShanghai
$22.60
-0.16 (-0.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-343.1M · quality 73.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.6B
P/E
N/A
•EV/EBITDA
39.8x
↑ROE
-4.6%
↓Gross Margin
23.6%
↓Debt/Equity
0.55
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.3%
FCF CAGR
—
FCF margin
-36.5%
FCF / Net income
4.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $940.2M · net income $-82.4M · FCF $-343.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $940.2M | $940.2M | $1.20B | $1.36B | $1.18B |
| Net Income | $-82.4M | $-82.4M | $-100.7M | $121.2M | $104.4M |
| EBITDA | $84.1M | $84.1M | $20.4M | $250.7M | $210.2M |
| EPS | — | — | -0.90 | 0.97 | 0.92 |
| Gross Margin | 23.6% | 23.6% | 27.8% | 26.6% | 22.8% |
| Operating Margin | -3.2% | -3.2% | 3.1% | 10.0% | 8.5% |
| Net Margin | -8.8% | -8.8% | -8.4% | 8.9% | 8.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.55 | 0.55 | 0.42 | 0.35 | 0.07 |
| Current Ratio | 1.87 | 1.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-343.1M | $-343.1M | $-368.2M | $-311.5M | $-158.2M |
| Returns | |||||
| ROE | -4.6% | -4.6% | -5.4% | 6.0% | 5.7% |
| Valuation | |||||
| P/E | — | — | — | 27.39 | 22.82 |
| EV/EBITDA | 39.75 | 39.75 | 137.70 | 13.23 | 9.53 |
| P/B | 1.44 | 1.44 | 1.35 | 1.65 | 1.30 |
| Growth & Yield | |||||
| Revenue Growth | -21.5% | -21.5% | -11.7% | 15.0% | — |
| EPS Growth | — | — | -192.8% | 5.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+25.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.90 → n/d
Residual
+25.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.